A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)

Phase 2

Completed

• Conditions: Plaque Psoriasis
• Interventions: Drug: AUR101; Drug: Placebo

• Registration Number: NCT04855721
• Lead Sponsor: Aurigene Discovery Technologies Limited

Brief Summary

A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)

Detailed Description

This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate the efficacy and safety of AUR101 in patients with moderate-to-severe psoriasis.

Approximately 128 patients with chronic moderate-to-severe plaque psoriasis (defined as Psoriasis Area and Severity Index (PASI) ≥12 and Body Surface Area (BSA) involved ≥10%) will be randomized to four groups (three dose groups of AUR101 and one placebo group) in the ratio of 1:1:1:1.

The patients in each arm will receive AUR101 of 200 mg twice daily, 400 mg twice daily, 400 mg once daily or matching placebo for 16 weeks in a double blind, double dummy fashion. All patients will be followed up for 14 ± 2 days of their last dose for safety assessment.

Study Timeline

• Study First Submitted: 2021-04-15
• Study First Submitted QC: 2021-04-21
• Study First Posted: 2021-04-22
• Study Start: 2021-05-04
• Primary Completion: 2022-11-30
• Status Verified: 2022-12
• Study Completion: 2022-12-10
• Last Update Submitted: 2022-12-11
• Last Update Posted: 2022-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 141

Inclusion Criteria

1. Confirmed diagnosis of chronic plaque-type psoriasis, diagnosed at least 6 months before screening
2. Psoriasis of at least moderate severity, defined as PASI≥12 and involved BSA≥10 % at screening and Day 1
3. Static 5-point IGA modified [mod] 2011 scale of 3 or higher at screening and Day 1
4. Adult males or females, ≥ 18 to ≤ 70 years of age
5. Ability to communicate well with the investigator and to comply with the requirements of the entire study
6. Willingness to give written informed consent (prior to any study related procedures being performed) and ability to adhere to the study restrictions and assessments schedule

Exclusion Criteria

1. History of erythrodermic, guttate or pustular psoriasis within last 12 months
2. BMI < 18 or > 40
3. History of lack of response to ustekinumab, secukinumab or ixekizumab (or any therapeutic agent targeted to IL12, IL-17 or IL-23) at approved doses after at least 3 months of therapy
4. Current treatment or history of treatment for psoriasis with any investigational or approved IL-17, IL-12 or IL-23 antagonist biological agents (e.g. secukinumab, briakinumab, tildrakizumab, ustekinumab etc.) within 6 months prior to the first administration of study drug.
5. Current treatment or history of treatment for psoriasis with other investigational or approved biological agents (e.g. anti-TNFα inhibitors - adalimumab, etanercept, infliximab, alefacept etc.) within 3 months prior to the first administration of study drug
6. Current treatment or history of treatment for psoriasis with non-biological systemic medications or immunomodulators (including systemic steroids, apremilast, methotrexate, cyclosporine, acitretin, etc.) or phototherapy within 4 weeks prior to the first administration of study drug.
7. Treatment with medicated topical agents (having active pharmaceutical ingredient that can impact or interfere with the effect of the study drug) within 2 weeks prior to the first administration of study drug.
8. Evidence of organ dysfunction (e.g. liver dysfunction ≥ 1.5 X of ULN for ALT, AST or ALP or Total Bilirubin, or renal dysfunction of ≥ 1.5X of ULN of serum creatinine)
9. Any surgery requiring general anesthesia within 3 months prior to screening
10. History of malignancy within last 5 years except patients with non-melanoma skin cancer or carcinoma in situ of cervix who can participate in the study. Adequately treated cutaneous basal or squamous cell carcinoma are allowed.
11. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV Ab) at screening
12. Patient with known history of systemic tuberculosis or currently suspected or known to have active tuberculosis
13. Patient expected to be started on anti-tubercular therapy either for treatment or prophylaxis of tuberculosis
14. Suspected tuberculosis infection as evident from a positive QuantiFERON TB-Gold test (QFT) or Mantoux test (MT) at screening. Patients with a positive QFT or MT may participate in the study if further work up as per the opinion of the investigator (like Chest X-ray or CT scan of Chest or other locally acceptable method for diagnosing active tuberculosis) establishes that patient does not have active tuberculosis. Patients with latent tuberculosis should not be enrolled except when they are not planned to start prophylaxis for tuberculosis during the study period.
15. History of hypersensitivity or idiosyncratic reaction to any investigational ROR-gamma inhibitors or any of the excipients of study drug
16. History of alcohol or substance abuse that will affect compliance to study procedures/schedule as per Investigator opinion
17. Any previous gastrointestinal surgery or recent (within 3 months) / current history of gastrointestinal disease, that in the opinion of investigator, could impact the absorption of the study drug
18. Positive pregnancy test for women of child-bearing potential (WOCBP) at the screening or randomization visit
19. Male patients who are sexually active with WOCBP, not willing to use reliable contraception methods as mentioned in section 8.14
20. Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable contraceptive methods (hormonal contraceptive, IUD or any double combination of male or female condom, spermicidal gel, diaphragm, sponge, cervical cap). Please see section 8.14 for acceptable contraceptive practices
21. Has received any investigational biologic agents within 3 months or 5 half-lives (whichever is longer) prior to the first administration of study drug
22. Has received another new chemical entity/non-biologic investigational drug within 28 days or 5 half-lives of investigational drug (whichever is longer) prior to study day 1
23. History of other auto-immune disorders (except psoriasis and psoriatic arthritis) where treatment with systemic immunosuppressants is required
24. History of active infection and/or febrile illness within 7 days prior to Day 1. The infection adequately treated by antibiotics during the screening period as per investigator opinion will be allowed to undergo randomization, provided patient is stable for at least 7 days before randomization
25. Current swab-positive or suspected (under investigation) Covid-19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of person(s) with confirmed Covid-19 infection, at screening or Day 1
26. History or presence of any major medical illness (e.g. renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, or local active infection/infectious illness) or psychiatric disease, or clinically significant laboratory / ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study
27. History of any unstable cardiac (including Class III or IV congestive heart failure by New York Heart Association Criteria), respiratory, hepatic, renal or other systemic conditions within 3 months prior to first study drug administration
28. Use of herbal remedies, mega dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of study drug
29. Patients who have received live attenuated vaccine in the 4 weeks prior to the first administration of study drug -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AUR101 400 mg PO BID	AUR101	Patients will receive AUR101 / placebo in double blind, double dummy manner
Placebo	Placebo	Patients will receive AUR101 / placebo in double blind, double dummy manner
AUR101 200 mg PO BID	AUR101	Patients will receive AUR101 / placebo in double blind, double dummy manner
AUR101 400 mg PO QD	AUR101	Patients will receive AUR101 / placebo in double blind, double dummy manner

Primary Outcome Measures

Name	Time	Method
Proportion of patients achieving PASI 75 response (i.e. 75 percent reduction from baseline PASI [Psoriasis Area and Severity Index] score) at the end of week 12.	Week 12	PASI-75; A higher proportion of patients reaching PASI-75 means betterment in higher proportion of patients

Secondary Outcome Measures

Name	Time	Method
Plasma Pharmacokinetic parameters at week 4	Week 4	AUC0-8 (Area Under The Curve for 8 hours) after morning drug administration
Changes in Pulse Rate	From Day 1 through Follow Up Visit at Week 14	Pulse Rate changes during trial
Changes in Temperature	From Day 1 through Follow Up Visit at Week 14	Body temperature changes during trial
Changes in Respiratory Rate	From Day 1 through Follow Up Visit at Week 14	Respiratory Rate changes during trial
Proportion of patients achieving PASI 50, PASI 90 and PASI 100 response at week 12.	Week 12	PASI-50, PASI-90, PASI-100; A higher proportion of patients reaching PASI-50, PASI-90 or PASI-100 means betterment in higher proportion of patients
Proportion of patients achieving PASI 75 response (i.e. 75 percent reduction from baseline PASI [Psoriasis Area and Severity Index] score) at the end of week 4 and 8	Week 4 and Week 8	PASI-75; A higher proportion of patients reaching PASI-75 means betterment in higher proportion of patients
Percent change from baseline in PASI score at week 12	Week 12	Percent Change in PASI from baseline
Percent change from baseline to week 12 in percent BSA involved	Week 12	Percent Change in BSA (body surface area) from baseline
Changes in QRS interval in ECG (Electro Cardio Gram)	Week 14 (Follow Up Visit)	Changes in QRS Interval
Changes in QTc interval in ECG (Electro Cardio Gram)	Week 14 (Follow Up Visit)	Changes in QTc Interval
Changes in CBC (Complete Blood Count)	From Day 1 through Follow Up Visit at Week 14	Complete Blood Count (CBC)
Changes in Liver Function Tests	From Day 1 through Follow Up Visit at Week 14	Liver Function Tests (AST, ALT, Total Bilirubin)
Changes in PR interval in ECG (Electro Cardio Gram)	Week 14 (Follow Up Visit)	Changes in PR Interval
Changes in weight	From Day 1 through Follow Up Visit at Week 14	Weight (in pounds) will be measured at all visits and change in weight (in pounds) will be presented
Proportion of patients achieving DLQI score of 0 or 1 at week 12	Week 12	DLQI (Dermatology Life Quality Index) Score; Lower scores are better; Maximum score of 30 and minimum of 0
Proportion of patients achieving IGA 0 or 1 at week 12	Week 12	IGA (Investigator's Global Assessment); Lower scores are better
Nature and incidence of Treatment Emergent Adverse Events (TEAEs)	From Day 1 through Follow Up Visit at Week 14	All Adverse Events which occur from the administration of study drug
Changes in Blood Pressure	From Day 1 through Follow Up Visit at Week 14	Both systolic and diastolic Blood Pressure changes during trial will be measured

Trial Locations

Locations (25)

Dermatology Treatment & Research Center; 🇺🇸 Dallas, Texas, United States

Johnson Dermatology; 🇺🇸 Fort Smith, Arkansas, United States

First OC Dermatology; 🇺🇸 Fountain Valley, California, United States

Unison Clinical Trials; 🇺🇸 Sherman Oaks, California, United States

Clinical Science Institute; 🇺🇸 Santa Monica, California, United States

Skin Research Institute; 🇺🇸 Coral Gables, Florida, United States

Accel Research Sites - Deland CRU; 🇺🇸 DeLand, Florida, United States

FXM Clinical Research Fort Lauderdale; 🇺🇸 Fort Lauderdale, Florida, United States

Direct Helpers Research Center; 🇺🇸 Hialeah, Florida, United States

Abys New Generation Research Inc.; 🇺🇸 Hialeah, Florida, United States

FXM Clinical Research Miramar LLC; 🇺🇸 Miramar, Florida, United States

Medisearch Clinical Trials; 🇺🇸 Saint Joseph, Missouri, United States

The Dermatology Specialists; 🇺🇸 New York, New York, United States

Sadick Research Group; 🇺🇸 New York, New York, United States

Paddington Testing Co, Inc; 🇺🇸 Philadelphia, Pennsylvania, United States

Dermatology Research Associates; 🇺🇸 Los Angeles, California, United States

Center for Clinical Studies Ltd., LLP.; 🇺🇸 Webster, Texas, United States

FXM Clinical Research Miami LLC; 🇺🇸 Miami, Florida, United States

Northwest AR Clinical Trials Center; 🇺🇸 Rogers, Arkansas, United States

Moore Clinical Research, Inc.; 🇺🇸 Brandon, Florida, United States

Lenus Research & Medical Group, LLC; 🇺🇸 Sweetwater, Florida, United States

Floridian Reserach; 🇺🇸 Miami, Florida, United States

Great Lakes Research Group, Inc; 🇺🇸 Bay City, Michigan, United States

University Clinical Trials, Inc.; 🇺🇸 San Diego, California, United States

Dawes Fretzin Clinical Research Group, LLC; 🇺🇸 Indianapolis, Indiana, United States